Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1873-1883

  Riester, Markus ^a,b   Werner, Lillian ^a   Bellmunt, Joaquim ^h   Selvarajah, Shamini ^a,c   Guancial, Elizabeth A ^a   Weir, Barbara A ^d   Stack, Edward C ^a,c   Park, Rachel S ^a   O'Brien, Robert ^a   Schutz, Fabio A B ^a   Choueiri, Toni K ^a   Signoretti, Sabina ^b   Lloreta, Josep ^h   Marchionni, Luigi ^e   Gallardo, Enrique ⁱ   Rojo, Federico ^h   Garcia, Denise I ^a   Chekaluk, Yvonne ^c   Kwiatkowski, David J ^c   Bochner, Bernard H ^g   Hahn, William C ^a,d   Ligon, Azra H ^a,c   Barletta, Justine A ^c   Loda, Massimo ^a,c   Berman, David M ^f   Kantoff, Philip W ^a   Michor, Franziska ^a,b   Rosenberg, Jonathan E ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL DE SABADELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; PLATINUM DERIVATIVE;

ARTICLE; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DNA TRANSCRIPTION; GENE DOSAGE; GENE EXPRESSION; HUMAN; METASTASIS; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; ADULT; AGED; BLADDER TUMOR; CHROMOSOME 1; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MALE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; URINARY TRACT CANCER;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 1; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84898736451     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0759     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
3. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17:3173-81. (Pubitemid 29470648)
4. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010;28:1850-5.
5. Hurst CD, Fiegler H, Carr P, Williams S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004;23:2250-63. (Pubitemid 38482541)
6. Kallioniemi A, Kallioniemi OP, Citro G, Sauter G, DeVries S, Kerschmann R, et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995;12:213-9.
7. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998;153:1615-21. (Pubitemid 28509919)
8. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 1994;151:545-60. (Pubitemid 24054683)
9. Hoglund M, Sall T, Heim S, Mitelman F, Mandahl N, Fadl-Elmula I. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 2001;61:8241-6. (Pubitemid 33091618)
10. Hurst CD, Platt FM, Taylor CF, Knowles MA. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res 2012;18:5865-77.
11. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005;11:7012-22. (Pubitemid 41428761)
12. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012;18:1323-33.
13. Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, et al. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. Cancer Res 2009;69:3810-8.
14. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 2010;9:3.
15. Sanchez-Carbayo M, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89. (Pubitemid 46622045)
16. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-22. (Pubitemid 40136776)
17. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and con fident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011;12:R41.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
19. Salari K, Tibshirani R, Pollack JR. DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data. Bioinformatics 2010;26:414-6.
20. Fadl-Elmula I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005;4:1.
21. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994;54:531-8. (Pubitemid 24053197)
22. Lindgren D, Sjodahl G, Lauss M, Staaf J, Chebil G, Lovgren K, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS ONE 2012;7:e38863.
23. Lindgren D, Gudjonsson S, Sjödahl G, Hallden C, Chebil G, Veerla S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463-72.
24. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
25. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, et al. An integrated approach to uncover drivers of cancer. Cell 2010;143:1005-17.
26. Alcivar A, Hu S, Tang J, Yang X. DEDD and DEDD2 associate with caspase-8/10 and signal cell death. Oncogene 2003;22:291-7. (Pubitemid 36174186)
27. Arai S, Miyake K, Voit R, Nemoto S, Wakeland EK, Grummt I, et al. Death-effector domain-containing protein DEDD is an inhibitor of mitotic Cdk1/cyclin B1. Proc Natl Acad Sci U S A 2007;104:2289-94. (Pubitemid 46391390)
28. Stegh AH, Schickling O, Ehret A, Scaffidi C, Peterhansel C, Hofmann TG, et al. DEDD, a novel death effector domain-containing protein, targeted to the nucleolus. EMBO J 1998;17:5974-86. (Pubitemid 28474791)
29. Lv Q, Wang W, Xue J, Hua F, Mu R, Lin H, et al. DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res 2012;72:3238-50.
30. Deybach JC, Puy H, Robreau AM, Lamoril J, Da Silva V, Grandchamp B, et al. Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. Hum Mol Genet 1996;5:407-10. (Pubitemid 26069586)
31. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009;138:389-403.
32. Hassounah NB, Bunch TA, McDermott KM. Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin Cancer Res 2012;18:2429-35.
33. Nakagawa T, Kajitani T, Togo S, Masuko N, Ohdan H, Hishikawa Y, et al. Deubiquitylation of histone H2A activates transcriptional initiation via trans-histone cross-talk with H3K4 di- and trimethylation. Genes Dev 2008;22:37-49.
34. Vainberg IE, Lewis SA, Rommelaere H, Ampe C, Vandekerckhove J, Klein HL, et al. Prefoldin, a chaperone that delivers unfolded proteins to cytosolic chaperonin. Cell 1998;93:863-73. (Pubitemid 28257591)
35. Lopez V, Gonzalez-Peramato P, Suela J, Serrano A, Algaba F, Cigudosa JC, et al. Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA. J Transl Med 2013;11:182.
36. Fong D, Spizzo G, Mitterer M, Seeber A, Steurer M, Gastl G, et al. Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer. Ann Surg Oncol 2012;19:4330-6.
37. Gutwein P, Schramme A, Voss B, Abdel-Bakky MS, Doberstein K, Ludwig A, et al. Downregulation of junctional adhesion molecule-A is involved in the progression of clear cell renal cell carcinoma. Biochem Biophys Res Commun 2009;380:387-91.
38. McSherry EA, Brennan K, Hudson L, Hill AD, Hopkins AM. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase. Breast Cancer Res 2011;13:R31.
39. Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010;29:6569-80.
40. Wang Y, Lui WY. Transforming growth factor-beta1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion. Eur J Cancer 2012;48:3475-87.
41. Fabre-Lafay S, Monville F, Garrido-Urbani S, Berruyer-Pouyet C, Ginestier C, Reymond N, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007;7:73. (Pubitemid 46785011)
42. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011;39:D945-50.
43. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
44. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer research 2009;69:6694-703.
45. Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma. Folia Histochem Cytobiol 2011;49:26-33.
46. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, et al. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene 2001;20:7686-93. (Pubitemid 33111868)
47. Magnani L, Ballantyne EB, Zhang X, Lupien M. PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet 2011;7:e1002368.
48. Futreal PACL, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, et al. A census of human cancer genes. Nat Rev Cancer 2004;4:177-83. (Pubitemid 38337497)